Core Viewpoint - Capstone Bio (300639.SZ) reported its Q3 2025 results, highlighting a significant institutional investment presence with 43.69% of total shares held by six institutional investors as of October 28, 2025 [1] Institutional Holdings - A total of 6 institutional investors disclosed holdings in Capstone Bio, amounting to 282 million shares, which represents 43.69% of the company's total equity [1] - The institutional holding percentage increased by 0.13 percentage points compared to the previous quarter [1] Public Fund Holdings - One public fund, the Medical Device ETF, increased its holdings during this period, with an increase percentage of 0.21% [1] - A total of 46 public funds did not disclose their holdings in this quarter, including notable funds such as Guojin Quantitative Multi-Factor A, E Fund CSI Wande Biotechnology Index (LOF) A, and others [1]

Core Viewpoint - Guanhao Bio (300238.SZ) reported its Q3 2025 results, highlighting a total institutional ownership of 75.83 million shares, representing 28.60% of the company's total equity, with a slight decrease in institutional ownership compared to the previous quarter [1] Institutional Ownership - As of October 28, 2025, six institutional investors disclosed their holdings in Guanhao Bio, with a combined ownership of 75.83 million shares, accounting for 28.60% of total shares [1] - The total institutional ownership decreased by 0.74 percentage points compared to the previous quarter [1] Public Fund Holdings - One public fund, the Medical Device ETF, increased its holdings during this period, with an increase in ownership percentage of 0.28% [1] - A total of 33 public funds that did not disclose their holdings in the previous quarter include notable names such as CITIC Securities Rotation Mixed A and CITIC Securities Selected Mixed A [1] Foreign Investment - The report indicates that BARCLAYS BANK PLC is the foreign institution that did not disclose its holdings in this quarter compared to the previous one [1]

Core Viewpoint - Meikang Bio (300439.SZ) reported its Q3 2025 results, highlighting a slight increase in institutional ownership and changes in public fund holdings [1] Institutional Investors - As of October 28, 2025, two institutional investors disclosed holdings in Meikang Bio A-shares, totaling 41.41 million shares, which represents 10.78% of the total share capital [1] - The institutional ownership increased by 0.03 percentage points compared to the previous quarter [1] Public Funds - One public fund, the Medical Device ETF, increased its holdings, contributing to a rise of 0.21% in ownership [1] - A total of 33 public funds did not disclose their holdings in this period, including notable funds such as E Fund CSI Wind Bio-Tech Index (LOF) A and others [1]

Core Insights - He Yuan Bio (688238.SH) released its Q3 2025 financial report on October 28, 2025, indicating a total of 73.72 million shares held by five institutional investors, accounting for 11.36% of the company's total share capital [1] - The institutional holding percentage decreased by 1.53 percentage points compared to the previous quarter [1] Institutional Investors - The five institutional investors include Shanghai Zhangjiang Technology Venture Capital Co., Ltd., Zhejiang Huarui Shengyin Venture Capital Co., Ltd., Shanghai Tanying Investment Partnership (Limited Partnership), Shanghai Zhangjiang Torch Venture Capital Co., Ltd., and Shanghai Ouli Investment Management Center (Limited Partnership) [1] - The total institutional holding percentage stands at 11.36% [1] Public Funds - In this period, 67 public funds were not disclosed compared to the previous quarter, including notable funds such as Huatai-PB CSI Precision Medical Index (LOF) A, SSE Composite Index ETF, Guotai SSE Comprehensive ETF, and others [1]

Group 1 - Berry Genomics (000710.SZ) released its 2024 annual report on April 25, 2025, indicating that as of April 24, 2025, 44 institutional investors disclosed holding A-shares, totaling 79.7934 million shares, which accounts for 22.57% of the total share capital [1] - The top ten institutional investors include Chengdu Tianxing Instrument (Group) Co., Ltd., Hongling Siqi (Zhuhai) M&A Equity Investment Enterprise (Limited Partnership), and others, with a combined holding ratio of 22.43%, reflecting a decrease of 1.55 percentage points compared to the previous quarter [1] - In the public fund sector, 37 new public funds were disclosed this period compared to the previous quarter, including funds such as Huatai-PB CSI Precision Medicine Index (LOF) A and Medical Device ETF [1] Group 2 - Foreign institutional investors that did not disclose holdings this period include MORGAN STANLEY & CO. INTERNATIONAL PLC, BARCLAYS BANK PLC, and J.P. Morgan Securities PLC - proprietary funds [2]

Group 1 - The core viewpoint of the news is that TuoJing Life (300642.SZ) has disclosed its annual report for 2024, revealing significant changes in institutional and foreign investment holdings [1] - As of April 19, 2025, a total of 42 institutional investors hold shares in TuoJing Life, with a combined holding of 36.8578 million shares, accounting for 22.61% of the total share capital [1] - The top ten institutional investors collectively hold 22.38% of the shares, which represents a decrease of 5.93 percentage points compared to the previous quarter [1] Group 2 - In terms of public funds, 36 new public funds have been disclosed this period compared to the previous quarter, including several notable funds such as the Medical Device ETF and the West China Quantitative Growth Mixed A [1] - Regarding foreign investment, only one foreign fund, UBS AG, has reduced its holdings, with a decrease of 0.31% [2] - Several foreign institutions, including MERRILL LYNCH INTERNATIONAL and Goldman Sachs, have not disclosed their holdings this period [2]